Modality
Small Molecule
MOA
EZH2i
Target
PRMT5
Pathway
Proteasome
CTCLMS
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
~Jun 2017
→ ~Sep 2018
Phase 2
Dec 2018
→ Feb 2029
Phase 2Current
NCT07907289
945 pts·CTCL
2018-12→2025-10·Terminated
NCT06010325
2,187 pts·CTCL
2020-11→2029-02·Not yet recruiting
3,132 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-08-277mo agoPh1 Dose Esc· CTCL
2025-10-086mo agoPh2 Data· CTCL
2029-02-172.9y awayPh2 Data· CTCL
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2
Termina…
P2
Not yet…
Catalysts
Ph1 Dose Esc
2025-08-27 · 7mo ago
CTCL
Ph2 Data
2025-10-08 · 6mo ago
CTCL
Ph2 Data
2029-02-17 · 2.9y away
CTCL
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07907289 | Phase 2 | CTCL | Terminated | 945 | Mayo |
| NCT06010325 | Phase 2 | CTCL | Not yet recr... | 2187 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 |